<DOC>
	<DOCNO>NCT00814593</DOCNO>
	<brief_summary>RATIONALE : Biological therapy , lymphokine-activated killer cell , may stimulate immune system different way stop tumor cell grow . Drugs use chemotherapy , Gliadel wafer , work different way stop growth tumor cell , either kill cell stop dividing . It yet know whether lymphokine-activated killer cell effective Gliadel wafer treat patient glioblastoma multiforme . PURPOSE : This randomized phase II trial study side effect well lymphokine-activated killer cell work compare Gliadel wafer treat patient newly diagnose glioblastoma multiforme remove surgery .</brief_summary>
	<brief_title>Lymphokine-Activated Killer Cells Gliadel Wafer Treating Patients With Newly Diagnosed Glioblastoma Multiforme That Can Be Removed Surgery</brief_title>
	<detailed_description>OBJECTIVES : - To compare side effect , include infection and/or abnormal heal surgery site , associate intralesional lymphokine-activated killer ( LAK ) cell vs polifeprosan 20 carmustine implant ( Gliadel® wafer ) consolidation therapy patient newly diagnose resectable glioblastoma multiforme . - To compare overall survival patient treat regimen . OUTLINE : Patients stratify accord age ( &lt; 50 v ≥ 50 year age ) , Karnofsky performance status ( 70-80 % vs 90-100 % ) , use corticosteroid &gt; 4 mg/day ( yes v ) , progressive disease first-line therapy ( yes v ) . Patients randomize 1 2 treatment arm . - Arm I : Patients undergo intracranial placement polifeprosan 20 carmustine implant ( Gliadel® wafer ) time therapeutic craniotomy . - Arm II : Patients undergo leukapheresis obtain autologous lymphokine-activated killer ( LAK ) cell , follow 3-7 day later therapeutic craniotomy . The autologous LAK cell instill tumor bed cavity time therapeutic craniotomy . After completion study treatment , patient follow periodically 5 year .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm primary malignant glioblastoma multiforme ( GBM ) ( i.e. , grade IV anaplastic astrocytoma ) Must undergone standard primary therapy ( e.g. , surgery , radiotherapy , temozolomide ) within past 90 day Additional anticancer therapy part firstline therapy , include radiosurgical procedure ( e.g. , stereotactic gamma knife radiosurgery ) allow Must operable candidate willing undergo craniotomy PATIENT CHARACTERISTICS : Karnofsky performance status 70100 % Life expectancy ≥ 2 month Hemoglobin &gt; 10.0 g/dL AGC &gt; 1,500/mm³ Platelet count &gt; 100,000/mm³ Serum total bilirubin &lt; 1.5 time upper limit normal ( ULN ) ALT AST &lt; 2.5 time ULN Serum creatinine &lt; 1.5 time ULN Negative pregnancy test Resides United States America Venous access available leukapheresis procedure obtain peripheral blood mononuclear cell No diagnosis invasive cancer within past 5 year , except situ carcinoma basal cell carcinoma localize squamous cell carcinoma skin Patients prior diagnosis minimal microscopic cancer ( e.g. , colonic polyp stage I prostate cancer Gleason score &lt; 6 ) may eligible , determine principal investigator No concurrent serious medical psychiatric illness may interfere give informed consent conduct study No known hypersensitivity allergy either carmustine aldesleukin PRIOR CONCURRENT THERAPY : See Disease Characteristics At least 3 week since prior anticancer therapy recover No polifeprosan 20 carmustine implant ( Gliadel® wafer ) time prior surgery GBM No prior treatment progressive disease No concurrent anticancer therapy ( e.g. , continuation hormonal therapy breast prostate cancer diagnose &gt; 5 year ago )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
	<keyword>adult glioblastoma</keyword>
</DOC>